A Kinetic Study Investigating Lipoprotein Metabolism Before and After the Administration of REGN1500, an ANGPTL3 Inhibitor, in Patients With Homozygous Familial Hypercholesterolemia. A Sub-study for Subjects Enrolled in the R1500-CL-1331 Clinical Trial
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- 05 May 2021 Results evaluating production and catabolic rates of apoB-containing lipoproteins before and after receiving evinacumab published in the Arteriosclerosis Thrombosis and Vascular Biology
- 02 Feb 2021 New trial record